Automated three-dimensional total-body photography improves the efficiency of positive malignant biopsies and reduces ...

Genentech’s label expansion for TNKase consolidates its market position for pharmacological stroke treatments.

Top 20 biopharma goes live with Veeva Development Cloud to speed the delivery of treatments for currently incurable diseases "Together with Veeva, Boehringer has advanced its approach to clinical ...

(Image Credits: Pixabay) Boehringer Ingelheim’s blockbuster diabetes drug, Empagliflozin, is now off-patent in India, paving the way for domestic drugmakers to launch generic versions.

Boehringer Ingelheim says it is on track to launch 25 new treatments in its human pharma division onto the market between now and 2030, fuelled by an R&D pipeline that it says is the best in its ...

On Tuesday, Boehringer Ingelheim’s Empagliflozin became off-patent in India. Major domestic drugmakers are expected to launch their generic versions soon. According to the company’s statement ...

Boehringer Ingelheim has a second positive trial under its belt for nerandomilast in pulmonary fibrosis, setting up regulatory filings. The new data from the 1,178-patient FIBRONEER-ILD study ...

And a baby chimpanzee sips a bottle. The 2024 Nature Photography Contest showcases the complicated beauty and inspiring resiliency of our planet. Photographer Christopher Paetkau took home top ...

Boehringer Ingelheim markets Activase and TNKase under the brand names Actilyse and Metalyse, respectively, outside the US, Canada and Japan.